Novel Organic Kale Products for Prevention of Obesity/Type 2 Diabetes
NCT ID: NCT04298970
Last Updated: 2023-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
34 participants
INTERVENTIONAL
2020-03-03
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Consuming a product containing 35-40 gram of freeze dried kale a day.
Intervention
Freeze-dried Brassica oleracea var. acephala
Placebo
Consuming a placebo product.
Placebo
Placebo product
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intervention
Freeze-dried Brassica oleracea var. acephala
Placebo
Placebo product
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diabetes debut \> 30 year
* Plasma fasting blood glucose \> 4mM and \< 12 mM
* HbA1c \> 43 and ≤ 108 mmol/mol
* BMI between 23-40 kg/m2
* Fasting triglyceride \> 1.7 mmol/L and HDL-cholesterol, men: \< 1.03 mmol/L and women: 1.29 mmol/L.
Exclusion Criteria
* In treatment with insulin, systemic glucocorticoids, glitazones or GLP-1 analogs.
* Cardiovascular-, physiological-, neurological-, and/or kidney diseases.
* Alcohol- or pill abuse.
* Acute diseases.
* Blood pressure ≥ 160/100
* Pregnant or breastfeeding women.
30 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Future Food Innovation
INDUSTRY
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Per Bendix Jeppesen
Associate. Prof, Phd, Diabetes and hormone diseases
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University
Aarhus C, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AU/AUH
Identifier Type: -
Identifier Source: org_study_id